Semaglutide and kidney disease: what the FLOW trial actually found

What the FLOW trial set out to measure

Chronic kidney disease affects roughly 850 million people worldwide. It is progressive, largely silent, and expensive to manage — most patients find out they have it when it is already moderate to severe. For people with type 2 diabetes, CKD is extremely common. Diabetes is the leading cause of kidney failure in the US. The two conditions feed each other.

The FLOW trial asked a direct question: does semaglutide slow kidney disease progression in people who have both? It enrolled 3,533 adults with type 2 diabetes and CKD at roughly 400 sites across 28 countries. Half got once-weekly semaglutide 1mg. Half got placebo. Median follow-up was 3.4 years.

It did not finish. An independent data monitoring committee stopped it early — before the planned endpoint — because the efficacy signal was clear enough that continuing a placebo arm was no longer considered ethical.

The 24% number — what it actually measures

The primary outcome was a composite: kidney failure, a sustained 50% or greater decline in eGFR (the standard measure of kidney filtration), or death from kidney or cardiovascular causes. A composite captures what actually matters clinically — not just a lab number, but dialysis, organ failure, death.

331 patients in the semaglutide group hit this outcome. 410 in the placebo group did. Hazard ratio 0.76, 95% CI 0.66 to 0.88. That is a 24% relative risk reduction with a confidence interval that does not touch 1.

The eGFR slope result — 1.16 ml/min/1.73m² per year slower decline — might sound modest. It compounds. CKD is a disease that takes years to reach kidney failure, and slowing the trajectory by that amount translates into years of preserved kidney function.

The cardiovascular finding hiding in the kidney data

The 29% reduction in cardiovascular death deserves its own sentence. The FLOW population was not selected for high cardiovascular risk — it was selected for kidney disease. Yet semaglutide cut CV death nearly as dramatically as dedicated cardiovascular outcomes trials have shown.

The SELECT trial — 17,604 patients, no diabetes required, purely cardiovascular focus — showed a 20% reduction in major cardiovascular events. FLOW, in a different population with a different primary endpoint, showed 29% lower CV death. These are not the same outcome measure, so you cannot compare them directly. But the pattern is consistent: semaglutide's cardiovascular effect is real and shows up across populations.

The ERA 2026 conference added a quality-of-life analysis. FLOW patients on semaglutide reported roughly 8 additional days per year in full health compared to placebo — a patient-reported outcome that translates what hazard ratios do not fully capture.

How semaglutide actually protects the kidney

The easy explanation is: it helps people lose weight and control blood sugar, and both of those help the kidneys. That is partly true. But it does not fully explain the effect size — or why the protection showed up so clearly in a trial that was not primarily about weight.

GLP-1 receptors exist in the kidney itself. They sit in the proximal tubule, the mesangial cells, and the endothelium of glomerular capillaries. When activated, they reduce inflammation in kidney tissue, lower intraglomerular pressure, and cut oxidative stress. Independent of weight. Independent of blood sugar.

Semaglutide also lowers systemic blood pressure and reduces sodium reabsorption in the proximal tubule — a mechanism similar to how SGLT2 inhibitors protect kidneys, though through different pathways. The two drug classes appear to be additive, not redundant, which is why combination therapy is increasingly common in high-risk CKD patients.

Who qualifies — and what the label actually says

The FDA approval is specific. It covers adults with type 2 diabetes and CKD — both conditions together. The indication is to reduce the risk of worsening kidney disease and cardiovascular death. The approved dose is semaglutide 1mg once weekly.

CKD is staged by eGFR and albuminuria. The FLOW trial enrolled patients across a range of CKD severity — not just early-stage disease. The benefit held across subgroups. Whether you have stage 3 or stage 4 CKD, the direction of effect was consistent.

The pattern: GLP-1s treating diseases they were not designed for

Semaglutide was approved for type 2 diabetes in 2017. Wegovy, the weight-loss version, came in 2021. Then the SELECT trial showed cardiovascular benefit in non-diabetics. Then the MASH trial showed liver disease reversal. Now kidney protection. The drug keeps expanding its indication list through large outcomes trials — and each one shows the same thing: the drug does more than control blood sugar or appetite.

Tirzepatide is following a similar path. Its approvals have come quickly for sleep apnea, heart failure with preserved ejection fraction, and additional metabolic indications beyond obesity. The GLP-1 class appears to be among the most broadly beneficial drug classes discovered — not because of a single mechanism, but because the receptors are in so many places that matter.

The kidney approval adds a specific population that needs this option badly. CKD is common, progressive, and often undertreated. The people most likely to benefit — diabetic patients with established kidney disease — are exactly who the FLOW trial enrolled. The evidence is as clean as large outcomes trial data gets.

Practical considerations for CKD patients

Semaglutide is generally well-tolerated in CKD. But kidney disease changes drug handling — slower clearance, altered volume of distribution, different sensitivity to side effects. GI side effects, which are common with GLP-1s, carry more risk in CKD patients who are already prone to dehydration. Nausea and vomiting can worsen kidney function acutely. Dose escalation needs to happen carefully.

Nephrology guidelines have updated to reflect the FLOW data. Many now list semaglutide as a first-line add-on for diabetic CKD patients already on SGLT2 inhibitors and renin-angiotensin system blockade. The combination — SGLT2 inhibitor plus semaglutide — appears additive because the two drugs work through different renal pathways. Whether your doctor has incorporated this into your care plan is worth asking about directly.